What are the common side effects of mobosetinib/mobosetinib?

Mobocertinib is a new oral targeted drug currently approved for the treatment of EGFR exon20 insertion mutation non-small cell lung cancer (NSCLC). This type of mutation is relatively rare in EGFR-positive lung cancer, but it is poorly tolerated clinically, and traditional EGFR-TKI drugs have limited efficacy. The emergence of mobosetinib has significantly expanded treatment options for these patients. However, as treatment time prolongs, drug-related side effects have become a common concern among patients.

The most common adverse reactions of moboxetinib include gastrointestinal symptoms, such as diarrhea, which is the most typical manifestation and has a high incidence rate. Sometimes it even affects daily life, and some patients require symptomatic support or dose reduction. In addition, symptoms such as nausea, loss of appetite, and vomiting are also common. They may begin to appear in the early stages of medication and may gradually alleviate over time, but some patients may still have symptoms.

Skin adverse reactions are also worthy of attention, including rash, dryness, itching, etc. These are usually related toEGFR inhibition mechanism and can be alleviated by using moisturizers, oral antihistamines, etc. Another important adverse reaction is fatigue, which occurs especially after several weeks of continuous medication, which may be related to changes in electrolytes in the body, changes in liver function, or systemic inflammatory responses. Some patients may experience elevated liver enzymes or fluctuations in renal function, so it is recommended to regularly detect blood biochemical indicators and promptly monitor ALT, AST and creatinine levels.

Mobosetinib has fewer cardiac adverse effects, butQT interval prolongation still needs attention, especially in patients who are concurrently taking other heart-affecting drugs. The risk increases. When using strong CYP3A4 inhibitors in combination, you need to be alert to interference with drug metabolism, which may aggravate toxicity. Some patients may also develop oral ulcers, dry eyes, cough or difficulty breathing, etc. It is necessary to evaluate whether it is drug-related or caused by disease progression based on clinical symptoms.

Reference materials:https://en.wikipedia.org/wiki/Mobocertinib